Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

er-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys and Copegus are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Today, Rhodes ... nervous system stimulant indicated for the treatment of ... beginning Summer 2015. The announcement ... approval from the U.S. Food and Drug Administration ... extended-release formulation of methylphenidate capsule with an onset ...
(Date:5/22/2015)... REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today announced that interim chief executive officer ... 2015 Healthcare Conference and chief financial officer Tim ... Science Conference. Details of the two presentations are as ...
(Date:5/21/2015)... 2015  When Ryan Rendino first felt ... his neck, he figured it was a ... off from weight lifting. But ... A series of doctor appointments ... Michel Kliot, MD , a ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... 24, 2012   Sanovas , a leading developer ... cancer and chronic diseases, announced today that it ... manufacturing site in Sausalito, Calif. The facility will ... of filing for U.S. Food and Drug Administration ...
... Medical Inc. (OTCBB:ONCS), which is developing its ... therapies to treat solid tumor cancers, today announced ... OncoSec, will be presenting at the World Cancer ... (Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) ...
Cached Medicine Technology:Sanovas Expands Headquarters and Opens Manufacturing Site 2OncoSec to Present at World Cancer Immunotherapy Conference 2OncoSec to Present at World Cancer Immunotherapy Conference 3
(Date:5/24/2015)... (PRWEB) May 24, 2015 Women's ... about hair loss. Although it is unclear about the ... are environmental factors such as metabolism, nutritional deficiencies, thyroid ... they offer a comprehensive approach to evaluating the metabolic, ... woman, they can help patients find a cause for ...
(Date:5/24/2015)... May 24, 2015 Scientists with Cardno ... on air quality compliance issues that may have raised ... Surviving Mesothelioma has just posted an article on the ... , The group found airborne asbestos levels well above ... between 1984 and 2011. , “Asbestos compliance sampling data ...
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin ... ProPin to pin point locations on a map, to indicate prices ... allows users to choose from 30 simplistic presets with geometric design ... video editors can easily manipulate ProPin presets as a whole. ... ease. , Using ProPin is easy, simply drag a preset into ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... 23, 2015 On May 13, Nithyananda ... a youngster's yogic power learned through meditation and initiation ... in Bangalore, India. , Yogamaatha, a nine-year-old girl from ... high profile professionals attending the 2015 Business Advocacy Summit ... -- blindfolded. , In a demonstration that lasted ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... Ceylan, from Turkey evaluated their experience in 48 cases ... ages ranged from 5 months to 24 years with ... performed at various centers or during religious ceremonies in ... found that the most commonly observed complication was preputio-glandular ...
... toxic chemicals and industrial effluents in sea and soil could increase ... obesity was thought to be the most important factor in the ... body does not produce enough insulin - necessary for the body ... by South Korean researchers has shown that people whose bodies are ...
... casts a shadow the length of a lifetime.” , - Herbert ... Sana was home alone, happy in her imaginative world of fairies ... neighborhood household. A knock on the door jolted her out of ... man, her uncle, was a devil in disguise. He locked the ...
... men, the erectile-dysfunction drugs Viagra, Cialis, and Levitra are ... in Midlife and Beyond,// a new report from Harvard ... the emotional and relationship pressures that frequently accompany erectile ... work only if the man is feeling sexual desire ...
... Australia’s already pressured hospital system would struggle to cope ... of a large-scale emergency, say trauma and emergency specialists.// ... preparedness targets for Australasian hospitals, says Dr Anthony Joseph, ... ,In the latest Medical Journal of ...
... A study conducted recently has shown that students who ... tendencies // like those who did not participate in ... not create the desired positive impact. ... being spent by the Federal government annually on the ...
Cached Medicine News:Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:Can Our Hospitals Cope In A Disaster? 2
... the way for faster, easier, and more ... utilizes the latest digital FireWire technology, allowing ... images. Its ease of use allows technicians ... extraordinary time reduction frees technicians to perform ...
... The ADVIA 1200 system features a small footprint, which ... , , Standardization as Part of the ADVIA ... same reagents, calibrators and controls as the other members ... the same proven reliability. , , Meets Workload ...
... The Stryker Wedge Suture Anchors are ... sizes and styles. The Wedge anchors are ... surgeon and OR staff. The following sizes ... 1 Suture, 5.0mm Single Eyelet 2 Sutures, ...
RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
Medicine Products: